Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : WAND (Milestone Scientific) -- Ignore unavailable to you. Want to Upgrade?

To: Brooks Jackson who wrote (558)	6/5/1998 2:14:00 PM
From: Robert L. Jacobs	Read Replies (2) \| Respond to of 717

Brooks, While I was composing my summary, I see you posted your own. While we each included some different details, I think we both came away with roughly the same story and conclusions, and I think those who were unable to hear the conference call will get a pretty good slant on what happened if they read both summaries!

To: Brooks Jackson who wrote (558)	6/6/1998 12:31:00 PM
From: Richard	Read Replies (2) \| Respond to of 717

I am a minimal investor in the Wand. I was disappointed with the conference call. What the investor wants to hear is that the Wand WORKS. The dozens of detractors in all their notices on this bulletin board have not refuted this basic truth. The Wand has gone through innumerable sources of scrutiny, including the FDA, ADA, and a number of reports by outstanding dentists. (whether it was improper that they were paid with options doesn't concern me, because I believe they would not jeopardize their very distinguished careers by saying a worthless product is good.) But, instead of hitting home with what won for MS in the past which are facts and reports, the MS spokesman only talked about a few examples at Monarch and then theorized about bell curves. MS missed a great opportunity when a dentist called to ask how he may be convinced. It was a good time to cite the details of these studies, thus not only possibly making an additional sale, but most importantly, reassuring investors listening in. Instead, the MS spokesman took down the dentist's name and phone number, which came across as evasive. MS's strategy of buying back stocks is great. But the rest is off the mark. Only truth convinces the investors. It is indisputable there is a slow down of sales at the moment. Rather than theorizing with bell curves etc. which convinces no one, MS should immediately do a thorough survey of the clients who bought the Wand. How many are satisfied? How many are not, and why? How many used it and went back to the syringe? The clients are the dentists and, in the end, their patients, which is just about everyone everywhere. The potential is mind-boggling. MS must first find out the truth from their clients who are the users and pay the money. Publish the surveys. After the surveys much of the reason for the slowdown will come out. If the product or the business operation need improvement, then MS must address that. The surveys may indeed prove MS's bell curve theory. But then MS would not be just hypothesizing. In the end, I believe if the average Joe (and especially their children) want a painless injection with little or no swelling after they leave the dental office, the Wand is a potential huge winner, regardless of anything else.